CJC1295 No Dac

CJC-1295 No DAC 5MG

Manufacturer: GetVital
Package: 5 mg/vial
Common Names: CJC-1295 No DAC, CJC-1295 Without DAC, Modified GRF 1-29, Mod GRF 1-29, GHRH 1-29

Info: CJC-1295 No DAC is a synthetic peptide derived from growth hormone-releasing hormone (GHRH). Unlike CJC-1295 with DAC, the No DAC variant does not contain the Drug Affinity Complex, resulting in a shorter duration of activity. It has been investigated for its interaction with GHRH receptors and its influence on pathways associated with endogenous growth hormone release. 

Effects

Growth Hormone Research: CJC-1295 No DAC has been studied for its ability to interact with GHRH receptors and stimulate signaling pathways involved in endogenous growth hormone secretion. Research has examined its role in regulating the GH axis without directly supplying exogenous growth hormone.

Dosage Range and Duration of Use

CJC-1295 No DAC 5 mg (5 mg/vial): Each vial contains 5 mg of CJC-1295 No DAC in lyophilized form and requires appropriate preparation using sterile procedures before administration.

In research and experimental settings, subcutaneous administration typically ranges from 100 mcg to 200 mcg per dose. Due to the short half-life of the No DAC variant (Modified GRF 1-29), protocols commonly involve dosing one to three times daily, often co-administered with a GHRP (such as Ipamorelin) to maximize growth hormone secretion. Standard experimental cycles generally last between 8 to 12 weeks, with total duration and dosing frequency determined according to specific research objectives under professional supervision.

Side Effects

The complete safety profile of CJC-1295 No DAC has not been established for all routes of administration and research applications. Potential reactions may vary according to dosage, exposure, administration method, individual characteristics, and concurrent substances. Possible reactions may include injection-site irritation, redness, swelling, headache, dizziness, nausea, fatigue, changes in appetite, fluid balance, or other effects associated with hormonal activity.

Post-Cycle Therapy

CJC-1295 No DAC is a peptide and is not an anabolic steroid, androgenic compound, or testosterone-suppressing anabolic agent. It therefore does not require conventional post-cycle therapy (PCT) protocols associated with anabolic steroid use. As a research peptide that influences GHRH and growth hormone signaling, its use should nevertheless remain within an appropriate medical or scientific framework.

Storage:

Store lyophilized CJC-1295 No DAC according to the manufacturer's storage specifications and protect the vial from excessive heat, moisture, and direct exposure to light. After reconstitution, storage requirements and stability may depend on the diluent, concentration, preparation method, and manufacturer's instructions.